Meanwhile, PHD inhibitors are reported to benefit cardiovascular disease in CKD patients through HIF, and HIF activation improves myocardial remodeling, atherosclerosis and vascular injury [189,190]. This evidence concerns the gene PDC and chronic kidney disease.